Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares Jun 29, 2023 08:30AM
Ironwood Pharma (IRWD) and VectivBio (VECT) Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio Jun 16, 2023 07:01AM
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio Jun 16, 2023 07:00AM
Ironwood Pharma (IRWD) to Acquire VectivBio (VECT) for $17/sh Cash May 22, 2023 06:57AM
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases May 22, 2023 06:57AM
View Older Stories

May 10, 2023 08:59AM VectivBio Publishes Invitation to the Annual General Meeting
Dec 9, 2022 04:01PM VectivBio Announces Results of Extraordinary General Meeting
Dec 9, 2022 04:01PM VectivBio Announces Results of Extraordinary General Meeting
Nov 16, 2022 07:30AM VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
Nov 16, 2022 07:30AM VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
Oct 12, 2022 10:00AM VectivBio Announces Date of Extraordinary General Meeting of Shareholders
Oct 12, 2022 10:00AM VectivBio Announces Date of Extraordinary General Meeting of Shareholders
Jun 9, 2022 04:16PM VectivBio Publishes Invitation to the Annual General Meeting
Jun 9, 2022 04:16PM VectivBio Publishes Invitation to the Annual General Meeting
Jun 2, 2022 08:15AM VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
Jun 2, 2022 08:15AM VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
May 9, 2022 07:30AM VectivBio to Participate at the Bank of America 2022 Healthcare Conference
May 9, 2022 07:30AM VectivBio to Participate at the Bank of America 2022 Healthcare Conference
Apr 21, 2022 07:15AM VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
Apr 21, 2022 07:15AM VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
Apr 7, 2022 07:15AM VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
Apr 7, 2022 07:15AM VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
Mar 30, 2022 08:07AM VectivBio Holding AG (VECT) Enters Japan License Deal and $117M Loan Facility Agreement
Mar 30, 2022 08:04AM VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
Mar 30, 2022 08:04AM VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
Mar 29, 2022 07:47AM VectivBio Holding AG (VECT) Reports New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure Patients Who Have Renal Dysfunction
Mar 29, 2022 07:45AM VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of P
Mar 29, 2022 07:45AM VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of P
Mar 23, 2022 07:16AM VectivBio (VECT) Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantati
Mar 23, 2022 07:15AM VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
Mar 23, 2022 07:15AM VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
Feb 8, 2022 07:15AM VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Feb 8, 2022 07:15AM VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Nov 10, 2021 08:30AM VectivBio Announces Third Quarter 2021 Business Update
Nov 10, 2021 08:30AM VectivBio Announces Third Quarter 2021 Business Update
Nov 4, 2021 07:15AM VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
Nov 4, 2021 07:15AM VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
Oct 20, 2021 07:15AM VectivBio (VECT) Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
Oct 20, 2021 07:15AM VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
Oct 20, 2021 07:15AM VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
Sep 21, 2021 07:15AM VectivBio Announces Closing of Comet Therapeutics Acquisition
Sep 21, 2021 07:15AM VectivBio Announces Closing of Comet Therapeutics Acquisition
Sep 16, 2021 07:15AM VectivBio Announces Upcoming Investor Events
Sep 16, 2021 07:15AM VectivBio Announces Upcoming Investor Events
Sep 8, 2021 07:15AM VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
Sep 8, 2021 07:15AM VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
Sep 3, 2021 07:15AM VectivBio Announces Results of Extraordinary General Meeting
Sep 3, 2021 07:15AM VectivBio Announces Results of Extraordinary General Meeting
Aug 31, 2021 07:00AM VectivBio Holding AG (VECT) Acquires Comet Therapeutics; Will Host R&D Day
Aug 31, 2021 07:00AM VectivBio to Acquire Comet Therapeutics and Host R&D Day
Aug 31, 2021 07:00AM VectivBio to Acquire Comet Therapeutics and Host R&D Day
View Older Stories